Last reviewed · How we verify
OSF Healthcare System — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
2 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| optimized ibuprofen | optimized ibuprofen | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | COX-1, COX-2 | Pain Management, Inflammation | |
| Stool | Stool | marketed | Other | |||
| knee injection | knee injection | phase 3 | Corticosteroid or Hyaluronic acid | Musculoskeletal | ||
| Shoulder injection | Shoulder injection | phase 3 | Orthopedics |
Therapeutic area mix
- Musculoskeletal · 1
- Orthopedics · 1
- Other · 1
- Pain Management, Inflammation · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Actavis Inc. · 1 shared drug class
- Amneal Pharmaceuticals, LLC · 1 shared drug class
- Amzell · 1 shared drug class
- Assaf-Harofeh Medical Center · 1 shared drug class
- Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Bayer · 1 shared drug class
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for OSF Healthcare System:
- OSF Healthcare System pipeline updates — RSS
- OSF Healthcare System pipeline updates — Atom
- OSF Healthcare System pipeline updates — JSON
Cite this brief
Drug Landscape (2026). OSF Healthcare System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/osf-healthcare-system. Accessed 2026-05-16.